Fair Value Measurements (Details 3) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Summary of the changes in the fair value of the non-current liability for contingent consideration:
Change in valuation	$ (9,843,000)	$ (5,945,000)	$ (66,235,000)	$ (23,195,000)
Proteolix
Liability for Contingent Consideration
Milestone payment based on the accelerated marketing approval of related parties, high end	365,000,000		365,000,000
Milestone payment based on the accelerated marketing approval of related parties, low end	0		0
Change in contingent considerations liability by 1% percentage increase or decrease in probability of occurrence of each milestone			2,300,000
Percent change to evaluate change in the contingent considerations liability			1.00%
Summary of the changes in the fair value of the non-current liability for contingent consideration:
Fair value at beginning of period			159,990,000	253,458,000
Payments			(80,000,000)
Change in valuation	9,800,000	5,945,000	66,235,000	23,195,000
Fair value at end of period	$ 146,225,000	$ 276,653,000	$ 146,225,000	$ 276,653,000